Outcomes of Hypothermia in Addition to Decompressive Hemicraniectomy in Treatment of Malignant Middle Cerebral Artery Stroke: A Randomized Clinical Trial.
Adult
Brain Edema
Decompressive Craniectomy
/ methods
Early Termination of Clinical Trials
Female
Hospital Mortality
Humans
Hypothermia, Induced
/ methods
Infarction, Middle Cerebral Artery
/ therapy
Male
Middle Aged
Mortality
Postoperative Care
/ methods
Proportional Hazards Models
Severity of Illness Index
Thrombectomy
Thrombolytic Therapy
Time-to-Treatment
Tracheostomy
/ statistics & numerical data
Journal
JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536
Informations de publication
Date de publication:
01 05 2019
01 05 2019
Historique:
pubmed:
19
1
2019
medline:
18
2
2020
entrez:
19
1
2019
Statut:
ppublish
Résumé
Moderate hypothermia in addition to early decompressive hemicraniectomy has been suggested to further reduce mortality and improve functional outcome in patients with malignant middle cerebral artery (MCA) stroke. To investigate whether moderate hypothermia vs standard treatment after early hemicraniectomy reduces mortality at day 14 in patients with malignant MCA stroke. This randomized clinical trial recruited patients from August 2011 through September 2015 at 6 German university hospitals with dedicated neurointensive care units. Of the patients treated with hemicraniectomy and assessed for eligibility, patients were randomly assigned to either standard care or moderate hypothermia. Data analysis was completed from December 2016 to June 2018. Moderate hypothermia (temperature, 33.0 ± 1.0°C) was maintained for at least 72 hours immediately after hemicraniectomy. The primary outcome was mortality rate at day 14 compared with the Fisher exact test and expressed as odds ratio (ORs) with 95% CIs. Rates of patients with serious adverse events were estimated for the period of the first 14 days after hemicraniectomy and 12 months of follow-up. Secondary outcome measures included functional outcome at 12 months. Of the 50 study participants, 24 were assigned to standard care and 26 to moderate hypothermia. Twenty-eight were male (56%); the mean (SD) patient age was 51.3 (6.6) years. Recruitment was suspended for safety concerns: 12 of 26 patients (46%) in the hypothermia group and 7 of 24 patients (29%) receiving standard care had at least 1 serious adverse event within 14 days (OR, 2.05 [95% CI, 0.56-8.00]; P = .26); after 12 months, rates of serious adverse events were 80% (n = 20 of 25) in the hypothermia group and 43% (n = 10 of 23) in the standard care group (hazard ratio, 2.54 [95% CI, 1.29-5.00]; P = .005). The mortality rate at day 14 was 19% (5 of 26 patients) in the hypothermia group and 13% (3 of 24 patients) in the group receiving standard care (OR, 1.65 [95% CI, 0.28-12.01]; P = .70). There was no significant difference regarding functional outcome after 12 months of follow-up. In patients with malignant MCA stroke, moderate hypothermia early after hemicraniectomy did not improve mortality and functional outcome compared with standard care, but may cause serious harm in this specific setting. http://www.drks.de, identifier DRKS00000623.
Identifiants
pubmed: 30657812
pii: 2721091
doi: 10.1001/jamaneurol.2018.4822
pmc: PMC6515837
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-579Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Références
Arch Neurol. 1984 Jan;41(1):26-9
pubmed: 6606414
N Engl J Med. 2002 Feb 21;346(8):557-63
pubmed: 11856794
Int J Stroke. 2017 Oct;12(7):732-740
pubmed: 28350280
Neurosurgery. 2009 Jan;64(1):86-92; discussion 92-3
pubmed: 19050656
Int J Stroke. 2015 Aug;10(6):941-9
pubmed: 26148223
Arch Neurol. 1996 Apr;53(4):309-15
pubmed: 8929152
N Engl J Med. 2015 Dec 17;373(25):2403-12
pubmed: 26444221
Lancet Neurol. 2009 Oct;8(10):949-58
pubmed: 19747656
Stroke. 2014 Apr;45(4):1222-38
pubmed: 24481970
Exp Neurol. 2008 Aug;212(2):386-92
pubmed: 18538766
Stroke. 2009 Dec;40(12):e657-65
pubmed: 19762706
N Engl J Med. 2002 Feb 21;346(8):549-56
pubmed: 11856793
Stroke. 2007 May;38(5):1585-9
pubmed: 17363720
JAMA. 2018 Dec 4;320(21):2211-2220
pubmed: 30357266
Stroke. 2010 Oct;41(10):2265-70
pubmed: 20724711
JAMA. 2013 Nov 27;310(20):2174-83
pubmed: 24105303
J Korean Neurosurg Soc. 2018 Mar;61(2):267-276
pubmed: 29526071
Int J Stroke. 2013 Jul;8(5):383-7
pubmed: 23782729
N Engl J Med. 2016 Dec 22;375(25):2457-2467
pubmed: 28002714
Stroke. 1984 May-Jun;15(3):492-6
pubmed: 6729878
Stroke. 2016 Dec;47(12):2888-2895
pubmed: 27834742
Cerebrovasc Dis. 2006;21(1-2):79-85
pubmed: 16330868
Brain. 2007 Dec;130(Pt 12):3063-74
pubmed: 17478443
Stroke. 2007 Sep;38(9):2506-17
pubmed: 17690311
Int J Stroke. 2011 Feb;6(1):79-86
pubmed: 21205246
Lancet Neurol. 2007 Mar;6(3):215-22
pubmed: 17303527
Neurocrit Care. 2015 Feb;22(1):146-64
pubmed: 25605626
Stroke. 2001 Sep;32(9):2117-23
pubmed: 11546905
J Cereb Blood Flow Metab. 2016 Jul;36(7):1157-64
pubmed: 27089911